Free Trial

PepGen Q3 2023 Earnings Report

PepGen logo
$2.30 -0.12 (-4.96%)
As of 01/17/2025 04:00 PM Eastern

PepGen EPS Results

Actual EPS
-$0.98
Consensus EPS
-$0.88
Beat/Miss
Missed by -$0.10
One Year Ago EPS
N/A

PepGen Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PepGen Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

PepGen Earnings Headlines

Stop guessing when stocks will move (use this)
Ever wonder why most traders make trading so complicated? Charts everywhere… Indicators on top of indicators… Eyes glued to screens all day. Here's something wild I discovered after analyzing 10 years of market data… The best trading system might just be... a calendar. Sounds crazy… But stick with me for a minute... I noticed that the most popular stocks have specific dates when they love to move up. Not random dates. Not "sometimes" dates. But precise windows of time that repeat year after year... for an entire decade.
See More PepGen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PepGen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PepGen and other key companies, straight to your email.

About PepGen

PepGen (NASDAQ:PEPG), a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

View PepGen Profile

More Earnings Resources from MarketBeat